Aldeyra Therapeutics IncNASDAQ:ALDX
- LAST PRICE4.1800
- TODAY'S CHANGE (%)0.0900 (2.2005%)
- Bid / Lots3.9100/ 5
- Ask / Lots4.3100/ 5
- Open / Previous Close4.0900 / 4.0900
- Day Range
- 52 Week Range
- Volume187,494
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | ALDX |
|---|---|---|
| 09:32 ET | 10247 | 4.05 |
| 09:34 ET | 300 | 4.05 |
| 09:36 ET | 400 | 4.1 |
| 09:38 ET | 2721 | 4.0989 |
| 09:41 ET | 5225 | 4.07 |
| 09:45 ET | 100 | 4.09 |
| 09:50 ET | 850 | 4.095 |
| 09:52 ET | 556 | 4.0715 |
| 09:54 ET | 615 | 4.12 |
| 09:56 ET | 100 | 4.12 |
| 09:59 ET | 100 | 4.11 |
| 10:01 ET | 100 | 4.08 |
| 10:03 ET | 100 | 4.07 |
| 10:08 ET | 3987 | 4.0799 |
| 10:14 ET | 3600 | 4.08 |
| 10:15 ET | 200 | 4.07 |
| 10:17 ET | 1362 | 4.0615 |
| 10:19 ET | 2555 | 4.08 |
| 10:21 ET | 1100 | 4.08 |
| 10:24 ET | 200 | 4.095 |
| 10:26 ET | 1026 | 4.11 |
| 10:32 ET | 2433 | 4.128 |
| 10:37 ET | 200 | 4.14 |
| 10:39 ET | 265 | 4.16 |
| 10:42 ET | 250 | 4.15 |
| 10:44 ET | 100 | 4.17 |
| 10:48 ET | 200 | 4.17 |
| 10:51 ET | 2398 | 4.16 |
| 10:53 ET | 4129 | 4.17 |
| 10:55 ET | 100 | 4.17 |
| 11:00 ET | 300 | 4.19 |
| 11:02 ET | 1735 | 4.19 |
| 11:04 ET | 855 | 4.17 |
| 11:06 ET | 300 | 4.1608 |
| 11:09 ET | 600 | 4.14 |
| 11:11 ET | 800 | 4.1301 |
| 11:13 ET | 600 | 4.14 |
| 11:24 ET | 1135 | 4.16 |
| 11:26 ET | 383 | 4.17 |
| 11:29 ET | 307 | 4.17 |
| 11:33 ET | 1600 | 4.175 |
| 11:36 ET | 100 | 4.175 |
| 11:38 ET | 100 | 4.175 |
| 11:42 ET | 500 | 4.165 |
| 11:44 ET | 6174 | 4.17 |
| 11:45 ET | 646 | 4.16 |
| 11:54 ET | 100 | 4.19 |
| 11:56 ET | 300 | 4.188 |
| 11:58 ET | 2485 | 4.17 |
| 12:05 ET | 100 | 4.18 |
| 12:14 ET | 100 | 4.18 |
| 12:16 ET | 12875 | 4.21 |
| 12:18 ET | 100 | 4.205 |
| 12:20 ET | 100 | 4.22 |
| 12:23 ET | 1700 | 4.22 |
| 12:25 ET | 200 | 4.205 |
| 12:30 ET | 200 | 4.22 |
| 12:32 ET | 1600 | 4.21 |
| 12:34 ET | 200 | 4.21 |
| 12:36 ET | 400 | 4.22 |
| 12:41 ET | 100 | 4.21 |
| 12:43 ET | 2356 | 4.2224 |
| 12:48 ET | 100 | 4.24 |
| 12:50 ET | 2600 | 4.215 |
| 12:56 ET | 654 | 4.22 |
| 01:01 ET | 233 | 4.21 |
| 01:03 ET | 100 | 4.21 |
| 01:12 ET | 100 | 4.22 |
| 01:17 ET | 2600 | 4.207 |
| 01:19 ET | 118 | 4.21 |
| 01:30 ET | 100 | 4.21 |
| 01:32 ET | 100 | 4.22 |
| 01:33 ET | 100 | 4.21 |
| 01:35 ET | 1197 | 4.2 |
| 01:37 ET | 100 | 4.2 |
| 01:39 ET | 145 | 4.1923 |
| 01:42 ET | 2764 | 4.21 |
| 01:44 ET | 896 | 4.2015 |
| 01:46 ET | 200 | 4.2 |
| 01:55 ET | 491 | 4.1918 |
| 02:00 ET | 867 | 4.185 |
| 02:02 ET | 2207 | 4.1858 |
| 02:06 ET | 100 | 4.185 |
| 02:09 ET | 580 | 4.185 |
| 02:11 ET | 200 | 4.19 |
| 02:15 ET | 1100 | 4.19 |
| 02:20 ET | 100 | 4.2 |
| 02:22 ET | 800 | 4.2 |
| 02:24 ET | 100 | 4.205 |
| 02:27 ET | 200 | 4.2 |
| 02:29 ET | 2864 | 4.2 |
| 02:33 ET | 1000 | 4.2093 |
| 02:36 ET | 1053 | 4.1989 |
| 02:38 ET | 200 | 4.2 |
| 02:40 ET | 200 | 4.19 |
| 02:42 ET | 100 | 4.1864 |
| 02:44 ET | 250 | 4.185 |
| 02:45 ET | 950 | 4.185 |
| 02:47 ET | 145 | 4.19 |
| 02:49 ET | 100 | 4.185 |
| 02:51 ET | 300 | 4.19 |
| 02:54 ET | 100 | 4.1953 |
| 02:56 ET | 200 | 4.195 |
| 02:58 ET | 1911 | 4.17 |
| 03:00 ET | 100 | 4.17 |
| 03:03 ET | 900 | 4.17 |
| 03:07 ET | 903 | 4.16 |
| 03:12 ET | 800 | 4.16 |
| 03:16 ET | 100 | 4.16 |
| 03:20 ET | 100 | 4.1572 |
| 03:21 ET | 100 | 4.16 |
| 03:25 ET | 885 | 4.14 |
| 03:30 ET | 200 | 4.15 |
| 03:32 ET | 3006 | 4.135 |
| 03:34 ET | 450 | 4.14 |
| 03:36 ET | 100 | 4.135 |
| 03:39 ET | 2640 | 4.14 |
| 03:41 ET | 100 | 4.14 |
| 03:43 ET | 2076 | 4.155 |
| 03:45 ET | 1125 | 4.1618 |
| 03:50 ET | 100 | 4.16 |
| 03:52 ET | 100 | 4.16 |
| 03:54 ET | 3879 | 4.18 |
| 03:56 ET | 902 | 4.18 |
| 03:57 ET | 2057 | 4.17 |
| 03:59 ET | 24109 | 4.18 |
May 29, 2024
Aldeyra Therapeutics to Participate in the Jefferies Global Healthcare Conference, from 7:00AM ET on Wednesday May 29, 2024 by Dow Jones
7:00AM ET on Wednesday May 29, 2024 by Dow Jones
May 8, 2024
May 6, 2024
DJ Aldeyra Therapeutics Price Target Maintained With a $10.00/Share by Oppenheimer, from 7:57AM ET on Monday May 06, 2024 by Dow Jones
7:57AM ET on Monday May 06, 2024 by Dow JonesDJ Aldeyra Therapeutics Price Target Maintained With a $10.00/Share by HC Wainwright & Co., from 6:48AM ET on Monday May 06, 2024 by Dow Jones
6:48AM ET on Monday May 06, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Aldeyra Therapeutics Inc | 229.3M | -8.2x | --- |
Design Therapeutics Inc | 228.8M | -4.0x | --- |
Eliem Therapeutics Inc | 224.3M | -16.3x | --- |
Opthea Ltd | 224.2M | -1.0x | --- |
XBiotech Inc | 220.8M | -7.1x | --- |
Acrivon Therapeutics Inc | 238.4M | -2.6x | --- |
Company Information
Aldeyra Therapeutics, Inc. is a biotechnology company, which is engaged in discovering therapies designed to treat immune-mediated diseases. The Company's product candidates include reactive aldehyde species (RASP) modulators ADX-629, ADX-246, ADX-248, and chemically related molecules for the treatment of systemic and retinal immune-mediated diseases. Its pre-commercial product candidates are reproxalap, a RASP modulator for the potential treatment of dry eye disease and allergic conjunctivitis, and ADX-2191, a novel formulation of intravitreal methotrexate for the treatment of proliferative vitreoretinopathy and retinitis pigmentosa. Its ADX-629, is an orally administered RASP modulator in clinical development for atopic dermatitis, idiopathic nephrotic syndrome, moderate alcohol-associated hepatitis, chronic cough, and Sjogren-Larsson Syndrome. Its preclinical RASP platform includes ADX-246 and ADX-248 in development for metabolic, retinal diseases and systemic inflammatory diseases.
Contact Information
- Headquarters
- 131 HARTWELL AVENUE, SUITE 320LEXINGTON, MA, United States 02421
- Phone
- 781-761-4904
- Fax
- 302-636-5454
Executives
- Independent Chairman of the Board
- Richard Douglas
- President, Chief Executive Officer, Director
- Todd Brady
- Senior Vice President - Finance, Interim Chief Financial Officer
- Bruce Greenberg
- Chief Development Officer
- Stephen Machatha
- Independent Director
- Ben Bronstein
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $229.3M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 59.4M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.39 |
EPS | $-0.51 |
Book Value | $2.02 |
P/E Ratio | -8.2x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
